black box warning for glp 1 agonists Tirzepatide injection (Zepbound®): Basic information prescribers Boxed Warning Medication Side Effects

On April 30, 2026, the FDA proposed to formally exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List, citing no clinical need for outsourcing facilities to compound these drugs from bulk substances

Matz tailors GLP-1 therapy to each patients unique needs, ensuring that it works effectively as part of a comprehensive weight loss plan

Additionally, SGLT2i can lower HbA1c levels by 0.5-1.0% and support weight loss ( Studies have indicated that increased expression of the sodium-hydrogen exchanger isoform 1 (NHE-1) is linked to heart failure and may contribute to the development of hypertrophy and cardiac injury during ischemia and reperfusion ( Of note, long-term use of SGLT2i may lead to a reduction in glycosuric efficacy, without a corresponding decline in cardiovascular benefits

Victoza (liraglutide) prescribing information

Theyre also approved for people with a BMI of 27 and at least one weight-related condition, like high blood pressure, high cholesterol, polycystic ovary syndrome (PCOS), or prediabetes

Common side effects include nausea, diarrhea, and constipation usually subsiding over time